Clinical trial NCT00103571: Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
Official title: Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Schizophrenia
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2005-02-11
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.


Eligibility criteria: Inclusion Criteria:

* Patients must have schizophrenia, schizoaffective disorder, or schizophreniform disorder
* Patients must be agitated
* Patients must display psychotic symptoms
* Patients must be inpatients who are expected to stay in the hospital for at least 5 days
* Patients must be 18 to 55 years of age

Exclusion Criteria:

* Patients may not be hospitalized for greater than 72 hours prior to study start
* Patients may not have received more than one dose of olanzapine or aripiprazole within 72 hours prior to study start
* Patients may not be actively suicidal
* Patients may not be diagnosed with substance-induced psychosis or substance dependence
* Patients may not have acute, serious, or unstable medical conditions

Primary outcomes:
measure: The primary objective of this study is to test the hypothesis that olanzapine is superior to aripiprazole in the reduction of symptoms of agitation in acutely ill patients with schizophrenia, as measured by mean change in the
measure: Positive and Negative Syndrome Scale Excited Component (PANSS-EC) over 5 days of treatment (4 continuous 24 hr treatment exposures). The null hypothesis of the study is that there is no difference between olanzapine and
measure: aripiprazole in reducing agitation.
Secondary outcomes:
measure: The reduction in positive symptoms as measured by the Brief Psychiatric Rating Scale Positive subscale (PBRS Positive);
measure: The reduction of symptoms of agitation as measured by Overt Agitation Severity Scale (OASS);
measure: The proportion of patients responding to treatment and the time to response based on varying levels in the percent reduction of
measure: the PANSS_EC from baseline;
measure: The reduction in overall severity of psychiatric illness as measured by the Clinical Global Impression-Severity Scale (CGI-S);
measure: The intensity of nursing intervention (e.g. seclusion, restraint, special nursing watch), as measured by the Global Assessment
measure: of Nursing Intervention
measure: The proportion of patients using pm lorazepam and the time-course of usage.
measure: The proportion of patients discontinuing from the study due to lack of efficacy or due to adverse events related to worsening
measure: of psychiatric illness.
measure: Patient satisfaction with their medication, as measured by Drug Attitude Inventory (DA1-10).
measure: A sensitivity analysis will be performed on two randomly chosen subsamples of the overall patient population by analyzing the
measure: primary objective respectively.
measure: Additional secondary objectives of the study are to compare the safety of olanzapine versus aripiprazole over the course of 5
measure: days in the treatment of acutely ill patients with schizophrenia as assessed by:
measure: Relative degree of sedation as measured by the Agitation Calmness Evalution Scale (ACES);
measure: Review of spontaneous (unsolicited) treatment emergent adverse events;
measure: Development of extrapyramidal symptoms as assessed by daily Modified Simpson-Angus and Barnes Akathisia scale scores.
Other outcomes:
Locations:
city: St Charles
country: United States
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
state: Missouri
city: Beachwood
country: United States
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
state: Ohio
city: Canton
country: United States
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
state: Ohio
city: Memphis
country: United States
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
state: Tennessee
city: Rio Piedras
country: Puerto Rico
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References: